guest ::
| Home > Publications database > Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective > print |
| Home > Publications database > Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective > print |
| 001 | 600080 | ||
| 005 | 20250724132556.0 | ||
| 024 | 7 | _ | |a 10.1021/acs.jmedchem.2c01887 |2 doi |
| 024 | 7 | _ | |a 0095-9065 |2 ISSN |
| 024 | 7 | _ | |a 0022-2623 |2 ISSN |
| 024 | 7 | _ | |a 1520-4804 |2 ISSN |
| 024 | 7 | _ | |a 1943-2992 |2 ISSN |
| 024 | 7 | _ | |a 10.3204/PUBDB-2023-07733 |2 datacite_doi |
| 024 | 7 | _ | |a altmetric:143423326 |2 altmetric |
| 024 | 7 | _ | |a pmid:36883902 |2 pmid |
| 024 | 7 | _ | |a WOS:000947818200001 |2 WOS |
| 024 | 7 | _ | |a openalex:W4323531069 |2 openalex |
| 037 | _ | _ | |a PUBDB-2023-07733 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Grygier, Przemyslaw |b 0 |
| 245 | _ | _ | |a Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective |
| 260 | _ | _ | |a Washington, DC |c 2023 |b ACS |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1704798876_313857 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a A clinical casein kinase 2 inhibitor, CX-4945 (silmitasertib), shows significant affinity toward the DYRK1A and GSK3β kinases, involved in down syndrome phenotypes, Alzheimer’s disease, circadian clock regulation, and diabetes. This off-target activity offers an opportunity for studying the effect of the DYRK1A/GSK3β kinase system in disease biology and possible line extension. Motivated by the dual inhibition of these kinases, we solved and analyzed the crystal structures of DYRK1A and GSK3β with CX-4945. We built a quantum-chemistry-based model to rationalize the compound affinity for CK2α, DYRK1A, and GSK3β kinases. Our calculations identified a key element for CK2α’s subnanomolar affinity to CX-4945. The methodology is expandable to other kinase selectivity modeling. We show that the inhibitor limits DYRK1A- and GSK3β-mediated cyclin D1 phosphorylation and reduces kinase-mediated NFAT signaling in the cell. Given the CX-4945’s clinical and pharmacological profile, this inhibitory activity makes it an interesting candidate with potential for application in additional disease areas. |
| 536 | _ | _ | |a 6G3 - PETRA III (DESY) (POF4-6G3) |0 G:(DE-HGF)POF4-6G3 |c POF4-6G3 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: bib-pubdb1.desy.de |
| 693 | _ | _ | |a PETRA III |f PETRA Beamline P11 |1 EXP:(DE-H253)PETRAIII-20150101 |0 EXP:(DE-H253)P-P11-20150101 |6 EXP:(DE-H253)P-P11-20150101 |x 0 |
| 700 | 1 | _ | |a Pustelny, Katarzyna |0 0000-0001-8430-8608 |b 1 |
| 700 | 1 | _ | |a Nowak, Jakub |b 2 |
| 700 | 1 | _ | |a Golik, Przemyslaw |b 3 |
| 700 | 1 | _ | |a Popowicz, Grzegorz M. |0 P:(DE-H253)PIP1086294 |b 4 |
| 700 | 1 | _ | |a Plettenburg, Oliver |b 5 |
| 700 | 1 | _ | |a Dubin, Grzegorz |b 6 |
| 700 | 1 | _ | |a Menezes, Filipe |0 P:(DE-HGF)0 |b 7 |e Corresponding author |
| 700 | 1 | _ | |a Czarna, Anna |0 P:(DE-H253)PIP1100543 |b 8 |e Corresponding author |
| 773 | _ | _ | |a 10.1021/acs.jmedchem.2c01887 |g Vol. 66, no. 6, p. 4009 - 4024 |0 PERI:(DE-600)1491411-6 |n 6 |p 4009 - 4024 |t Journal of medicinal chemistry |v 66 |y 2023 |x 0095-9065 |
| 856 | 4 | _ | |y OpenAccess |u https://bib-pubdb1.desy.de/record/600080/files/grygier-et-al-2023-silmitasertib-%28cx-4945%29-a-clinically-used-ck2-kinase-inhibitor-with-additional-effects-on-gsk3%CE%B2-and.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://bib-pubdb1.desy.de/record/600080/files/grygier-et-al-2023-silmitasertib-%28cx-4945%29-a-clinically-used-ck2-kinase-inhibitor-with-additional-effects-on-gsk3%CE%B2-and.pdf?subformat=pdfa |
| 909 | C | O | |o oai:bib-pubdb1.desy.de:600080 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 4 |6 P:(DE-H253)PIP1086294 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 8 |6 P:(DE-H253)PIP1100543 |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Materie |l Großgeräte: Materie |1 G:(DE-HGF)POF4-6G0 |0 G:(DE-HGF)POF4-6G3 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-600 |4 G:(DE-HGF)POF |v PETRA III (DESY) |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J MED CHEM : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J MED CHEM : 2022 |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-H253)HAS-User-20120731 |k DOOR ; HAS-User |l DOOR-User |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-H253)HAS-User-20120731 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|